The ECU Health Medical Center is expanding heart care with two new technologies for transcatheter tricuspid valve replacement. The new technologies are EVOQUE™, a ...

Where this device will fit in with other emerging options remains to be seen, but it might hold an advantage in large annuli.

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Two state-of-the-art new technologies for transcatheter tricuspid valve replacements is expanding advanced heart care with ...

Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat ...

Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

The BluePearl Pet Hospital in Tampa, Florida, is now offering the transcatheter edge-to-edge repair (TEER) procedure for its ...

Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies ...

AI algorithms can accurately identify tricuspid regurgitation in echocardiograms, supporting timely diagnosis and ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...